ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

CD38

CD38 molecule · also cADPR1 · CD molecules

11 programs in company-led studies act on CD38, from 10 companies: 6 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
daratumumabruleJohnson & Johnson–phase 44410 running–NCIt
lumrotatugruleKeymed Biosciences–phase 3108 running–NCIt
felzartamabruleBiogen–phase 3157 running–NCIt
isatuximabruleSanofi–phase 3236 running–NCIt
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Group–phase 355 running–NCIt
mezagitamabruleTakedaagonistphase 3114 running–NCIt
sanritatugruleHangzhou Sumgen Biotech–phase 354 running–NCIt
CID-103ruleCASI Pharmaceuticals–phase 232 running–NCIt
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbVie–phase 222 runningCD3E, TNFRSF17the company's pipeline
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceutical–phase 211 running–NCIt
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbVie–phase 111 running–the company's pipeline

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.